Telephone
61.2.9256.2505
Address
Level 23 180 George Street Salesforce Tower Sydney, New South Wales (NSW) 2000
Description
Recce Pharmaceuticals Ltd. is engaged in the research and development of pharmaceutical drugs that kill germs. It produces antibiotics that are effective in attacking disease-causing Gram-positive and Gram-negative bacteria. The company was founded on April 11, 2007 and is headquartered in Sydney, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.41 - 0.78
Trade Value (12mth)
AU$20,973.00
1 week
-2.25%
1 month
0%
YTD
-32.41%
1 year
-37.24%
All time high
1.85648
EPS 3 yr Growth
119.500%
EBITDA Margin
N/A
Operating Cashflow
-$13m
Free Cash Flow Return
-335.00%
ROIC
-345.30%
Interest Coverage
-93.40
Quick Ratio
0.40
Shares on Issue (Fully Dilluted)
180m
HALO Sector
Healthcare
Next Company Report Date
30-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
31 October 23 |
RCE Corporate Presentation at Ord Minnett Healthcare Forum
×
RCE Corporate Presentation at Ord Minnett Healthcare Forum |
31 July 23 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
31 January 22 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
31 January 18 |
Investor Presentation
×
Investor Presentation |
31 August 23 |
Appendix 4E and Unaudited Preliminary Report
×
Appendix 4E and Unaudited Preliminary Report |
31 August 23 |
Additional Positive Patient Cases - Special Access Scheme
×
Additional Positive Patient Cases - Special Access Scheme |
31 August 22 |
Appendix 4E
×
Appendix 4E |
31 August 22 |
Annual Report to shareholders
×
Annual Report to shareholders |
31 August 22 |
Appendix 4G
×
Appendix 4G |
31 August 21 |
Annual Report to shareholders
×
Annual Report to shareholders |
30 September 20 |
2020 Annual General Meeting
×
2020 Annual General Meeting |
30 October 20 |
Investor Presentation
×
Investor Presentation |
30 October 20 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
30 October 20 |
Letter to Shareholders - Annual General Meeting
×
Letter to Shareholders - Annual General Meeting |
30 November 20 |
RCE AGM Presentation
×
RCE AGM Presentation |
30 May 18 |
Recce Pharmaceuticals to Present at Investor Conference
×
Recce Pharmaceuticals to Present at Investor Conference |
30 March 22 |
Positive safety data from 4th Cohort -Phase I Clinical Trial
×
Positive safety data from 4th Cohort -Phase I Clinical Trial |
30 January 23 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
29 September 23 |
Application for quotation of securities - RCE
×
Application for quotation of securities - RCE |
29 September 23 |
Entitlement Offer - Announcement of Results
×
Entitlement Offer - Announcement of Results |
29 September 23 |
Annual Report to Shareholders
×
Annual Report to Shareholders |
29 September 23 |
Appendix 4G
×
Appendix 4G |
29 May 23 |
DFI Clinical Trial Outpatient Nurses Appointed
×
DFI Clinical Trial Outpatient Nurses Appointed |
29 June 23 |
Ethics Approval for Phase I/II UTI Trial Expansion
×
Ethics Approval for Phase I/II UTI Trial Expansion |
28 September 18 |
2018 Annual Report
×
2018 Annual Report |
28 October 22 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
28 March 22 |
$3.08m R&D Rebate Received
×
$3.08m R&D Rebate Received |
28 July 23 |
Scientia Completes Cohort Dosing in Phase I/II UTI Trial
×
Scientia Completes Cohort Dosing in Phase I/II UTI Trial |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.